- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ChemoCentryx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2021 - CCXI - Stockhouse
- The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors - Stockhouse
- Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. - Business Wire
- Why is there a pain in hand? - The Sangai Express
- Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop - Benzinga
- ChemoCentryx, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit - GlobeNewswire
- FDA Adcom Almost Evenly Split Vote on ChemoCentryx's Vasculitis Drug - BioSpace
- Mid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares Slide - Benzinga
- CCXI Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies ChemoCentryx, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm - Stockhouse
- Recent And Upcoming FDA Advisory Committee Meetings - Pink Sheet
- Mid-Morning Market Update: Markets Open Higher; US Adds Only 266000 Jobs In April - Benzinga
- ChemoCentryx (CCXI) Crashes 55% on Mixed AdComm Results, Gets Downgraded at Five Firms - StreetInsider.com
- CCXI INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud - Benzinga
- CCXI INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud - PRNewswire
- FDA Advisors Split on New Drug for Vasculitis - MedPage Today
Connect with us on social media!
Participate in Research
The Vasculitis Foundation's updated website design was generously funded with a grant by Genentech.
